Stage-specific associations between beta blocker use and prognosis after colorectal cancer

Authors

  • Lina Jansen PhD,

    Corresponding author
    1. Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany
    • Corresponding author: Lina Jansen, PhD, Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), POB 10 19 49, D-69009 Heidelberg, Germany; Fax: (011) +49-6221-421302; l.jansen@dkfz.de

    Search for more papers by this author
  • Michael Hoffmeister PhD,

    1. Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany
    Search for more papers by this author
  • Volker Arndt MD, MPH,

    1. Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany
    Search for more papers by this author
  • Jenny Chang-Claude PhD,

    1. Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany
    Search for more papers by this author
  • Hermann Brenner MD, MPH

    1. Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany
    2. German Cancer Consortium (DKTK), Heidelberg, Germany
    Search for more papers by this author

  • We thank Ute Handte-Daub and Petra Bächer for their excellent technical assistance. We are grateful to the study participants, the interviewers who collected the baseline data, and the hospitals and cooperating institutions that recruited patients for this study: Chirurgische Universitätsklinik Heidelberg, Klinik am Gesundbrunnen Heilbronn, St. Vincentiuskrankenhaus Speyer, St. Josefskrankenhaus Heidelberg, Chirurgische Universitätsklinik Mannheim, Diakonissenkrankenhaus Speyer, Krankenhaus Salem Heidelberg, Kreiskrankenhaus Schwetzingen, St. Marien- und St. Annastiftkrankenhaus Ludwigshafen, Klinikum Ludwigshafen, Stadtklinik Frankenthal, Diakoniekrankenhaus Mannheim, Kreiskrankenhaus Sinsheim, Klinikum am Plattenwald Bad Friedrichshall, Kreiskrankenhaus Weinheim, Kreiskrankenhaus Eberbach, Kreiskrankenhaus Buchen, Kreiskrankenhaus Mosbach, Enddarmzentrum Mannheim, Kreiskrankenhaus Brackenheim, and the Cancer Registry of Rhineland-Palatinate.

Abstract

BACKGROUND

Recent observational studies have suggested that the use of beta blockers might be associated with better prognosis after cancer. Because evidence is limited for colorectal cancer (CRC), the association of beta blocker use and prognosis was investigated in a large population-based cohort of patients with CRC.

METHODS

Between 2003 and 2007, information on beta blocker use at diagnosis and potential confounders was collected by personal interviews for 1975 patients with CRC. Vital status, cause of death, and recurrence status were assessed during a median follow-up time of 5.0 years. The associations of beta blocker use and overall, CRC-specific, and recurrence-free survival were estimated by Cox proportional hazard regression. In addition, beta blocker subgroup, site, and stage-specific analyses were performed.

RESULTS

After adjustment for covariates including sociodemographic, cancer-related, and lifestyle factors and comorbidity and medications, no significant association between beta blocker use at diagnosis and prognosis was observed for all stages combined. However, in stage-specific analyses, beta blocker use was associated with longer overall survival (hazard ratio = 0.50; 95% confidence interval = 0.33-0.78) and CRC-specific survival (hazard ratio = 0.47; 95% confidence interval = 0.30-0.75) in stage IV patients. For these patients, median overall survival was 18 months longer and CRC–specific survival was 17 months longer for beta blocker users than for nonusers (38 versus 20 months and 37 versus 20 months, respectively).

CONCLUSIONS

These results suggest that beta blocker use might be associated with longer survival in patients with stage IV CRC. Cancer 2014;120:1178–1186. © 2014 American Cancer Society.

Ancillary